Huisheng Bio’s self-developed GLP-1R/GCGR dual-target innovative drug P052 injection has been approved for clinical trials
September 11, 2025
Source: drugdu
126
Sihuan Pharmaceutical announced on the Hong Kong Stock Exchange on September 9 that its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. independently developed an innovative dual-target agonist drug for the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR).The clinical trial application for P052 Injection, a new drug, has received implicit approval from the Center for Drug Evaluation of the National Medical Products Administration (NMPA) for the treatment of type 2 diabetes, overweight, or obesity. P052 Injection not only stimulates the GLP-1 receptor to promote insulin secretion, lower blood sugar, and reduce weight, but also stimulates the GCGR to increase energy expenditure, enhance weight loss efficacy, and improve liver fat metabolism. Preclinical data show that P052 Injection, an innovative dual-target GLP-1R/GCGR drug , has similar glucose-lowering effects as the single-target GLP-1 drug semaglutide injection, and significantly superior weight loss efficacy to semaglutide injection.
Source: https://finance.eastmoney.com/a/202509093508169355.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
